Work

Supplementary Figure 6 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

Year: 2025
Type: supplementary-materials
Abstract: Supplementary Figure 6: In vivo response to elimusertib from pre-treatment biopsy PDX models.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
OpenAlex ID: W4413905599
Cites:
Cited by:
Related to: 10